Healthcare / BiotechnologyNasdaqCM
$2.07
+0.01 (+0.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.0M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
0.1x
↓EV/EBITDA
N/A
•ROE
-199.0%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-12.0M · FCF $-10.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | $0.00 | $100000.00 |
| Net Income | $-12.0M | $-12.0M | $-8.2M | $-13.0M | $-3.2M | $-9.3M | $-4.8M |
| EBITDA | $-12.0M | $-12.0M | $-8.2M | $-11.0M | $-2.6M | — | — |
| EPS | -121.80 | -121.80 | -1545.55 | -125355.77 | -47308.82 | -1845261.60 | -1390443.60 |
| Operating Margin | — | — | — | — | — | — | -4788.0% |
| Net Margin | — | — | — | — | — | — | -4822.0% |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.05 | -0.41 | — | — |
| Current Ratio | 14.21 | 14.21 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-10.2M | $-10.2M | $-8.6M | $-9.0M | $-1.1M | $-8.3M | $-3.7M |
| Returns | |||||||
| ROE | -199.0% | -199.0% | -203.5% | -5033.6% | 198.0% | 191.9% | 331.6% |
| Valuation | |||||||
| P/E | 0.05 | 0.05 | — | — | — | — | — |
| P/B | 0.03 | 0.03 | 0.70 | 5.69 | — | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | — | — | -100.0% | — |
| EPS Growth | 92.1% | 92.1% | 98.8% | -165.0% | — | -32.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-94.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1545.55 → -121.80
Residual
-94.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.